Back to News
Sep 22, 2025 12:00 PM

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

The acquisition brings a portfolio of differentiated oral and injectable incretin, non-incretin, and combination therapy candidates.

“Obesity is a large and growing space with over 200 health conditions associated with it,” said Pfizer CEO Albert Bourla. . The acquisition “propels” Pfizer into a “key therapeutic area,” he added.

Also Read: Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Metsera has a portfolio ...